About Hereditary Hemochromatosis
Hereditary hemochromatosis is the most common genetic disorder of iron metabolism in populations of Northern European descent, most often caused by homozygous C282Y mutations in the HFE gene. Unregulated intestinal iron absorption leads to progressive iron deposition in the liver, heart, pancreas, joints, and endocrine glands. Clinical manifestations include liver cirrhosis, cardiomyopathy, diabetes mellitus, arthropathy, and hypogonadism. Phlebotomy (blood removal) remains the cornerstone of treatment.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Hereditary Hemochromatosis trials.
Serum ferritin and transferrin saturation are the primary eligibility biomarkers — document pre-treatment and current levels
Liver iron concentration by MRI (MRI-LIC) or biopsy is often required for advanced disease trials
Phlebotomy frequency and volume history should be thoroughly documented — some trials require maintenance phase stability
Non-HFE forms (TFR2, HJV, HAMP mutations) are biologically distinct and may have separate or exclusionary eligibility criteria
Patient Resources
Find recruiting Hereditary Hemochromatosis trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Hereditary Hemochromatosis. Updated daily.